GDUFA: FDA Struggles Under Higher-Than-Expected Submission Volume
Executive Summary
Generic drugs office Acting Director Uhl says in interview that the agency does not know what its static workload will be yet after submissions exceed estimates in FY 2013.
You may also be interested in...
FDA Contradicts AAM's Generic Market Consolidation Argument
As the generic industry trade group warns shortages could emerge as number of manufacturers contracts, US FDA says many new firms gaining approvals and identifying facilities.
FDA Contradicts AAM's Generic Market Consolidation Argument
As the generic industry trade group warns shortages could emerge as number of manufacturers contracts, US FDA says many new firms gaining approvals and identifying facilities.
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.